B·R·A·H·M·S Biomarkers: Pre-eclampsia Management

Discover the power of prenatal screening on KRYPTOR for improved pre-eclampsia management  

Pre-eclampsia is a serious pregnancy complication which affects about 2-4% of pregnancies.1 This life-threatening disease can only be cured by the delivery of the baby and contributes largely to maternal and neonatal mortality and morbidity. Pre-eclampsia can start from week 20 and happens up to 6 weeks after delivery.2

 

Serum biomarkers such as PAPP-A, PlGF and sFlt-1 play a pivotal role in early identification of pregnancies at risk for maternal pre-eclampsia.

 

Experience the confidence that comes with our complete solution, backed by years of expertise and unwavering commitment to delivering excellence in prenatal care.

Understand best practices for pre-eclampsia management

preeclampsia-spotlight

Biomarker solutions for pre-eclampsia management

Use only the highest levels of precision in your lab

Thermo Scientific B·R·A·H·M·S Biomarkers for prenatal screening allow your lab to run with the highest precision and most reliable results.

Choose the highest quality for your patients

B·R·A·H·M·S Biomarkers for pre-eclampsia management help provide patients with the most accurate and precise risk calculations available.

Choose from a comprehensive test menu

The comprehensive menu of B·R·A·H·M·S Assays for pre-eclampsia risk assessment provide outstanding lot-to-lot stability and the highest precision.

Unlock the power of precision and reliability

Thermo Scientific B·R·A·H·M·S KRYPTOR Analyzers are fully automatic, closed laboratory analysis systems employing Nobel Prize winning TRACE technology.

Discover innovative biomarker solutions

B·R·A·H·M·S Biomarker solutions help to improve the early diagnosis and treatment of life-threatening diseases.

Explore helpful resources

Find resources to learn more about B·R·A·H·M·S Biomarkers for pre-eclampsia screening and the benefits of implementing these assays in your laboratory and clinic. 

References

1.     Magee LA et al. NEJM 2022;386:1817-32.

2.     ACOG practice bulletin 222 (2020).

Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.

 

© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.

 

KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.